| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.093 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.2 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.2 |